- Industry: Pharmaceuticals
- Founded: 1925
- Country: Denmark
- CEO: Lars Rebien Sørensen
- Website: www.novonordisk.com
Profile
Novo Nordisk A/S is a Denmark-based company
engaged in the discovery, development, manufacturing and marketing of
pharmaceutical products. The Company reports two business segments:
Diabetes care and Biopharmaceuticals. The Diabetes care division offers a
range of diabetes products, including insulin pens and needles, such as
FlexPen, NovoPen and FlexTouch, among others, and diabetes medicine,
such as insulin- and
non-insulin treatment, among others.
The Biopharmaceuticals division
provides products within the areas of haemophilia, growth hormone
therapy, hormone replacement therapy, inflammation therapy and other
therapy areas. As of December 31, 2012, the Company marketed its
products in five reported geographical regions, namely North America,
Europe, Region China, Japan and Korea, as well as International
Operations. The Company wholly owns over 70 subsidiaries, such as Novo
Nordisk Pharma GmbH, Novo Nordisk Canada Inc., Novo Nordisk Region Japan
& Korea A/S, among others.